8NE Stock Chart & Stats
€1.14
-€0.21(-15.56%)
At close: 4:00 PM EDT
€1.14
-€0.21(-15.56%)
Day’s Range― - ―
52-Week Range€0.74 - €4.34
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€10.25M
Enterprise Value€20.26M
Total Cash (Recent Filing)€10.44M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.64
Shares Outstanding10,804,066
10 Day Avg. Volume1
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.09
Price to Sales (P/S)95.05
P/FCF Ratio-1.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.97
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsEncouraging preliminary results from Cohort B of the ASCEND Phase 2b trial in metastatic pancreatic ductal adenocarcinoma.
Clinical TrialsEnrollment in the 1L cohort was completed nearly 6 months ahead of initial projections, accelerating the anticipated topline data readout to 4Q25.
Financial PerformanceLisata announced 2Q25 financial results, posting EPS of ($0.54) compared to our estimate of ($0.66) and consensus of ($0.65).
Bears Say
EarningsThe company ended the quarter with approximately $22 million in cash, which management believes can cover expenses for all ongoing and proposed trials with runway into 4Q26.
Lisata Therapeutics News
8NE FAQ
What was Lisata Therapeutics’s price range in the past 12 months?
Lisata Therapeutics lowest stock price was €0.73 and its highest was €4.34 in the past 12 months.
What is Lisata Therapeutics’s market cap?
Lisata Therapeutics’s market cap is €10.25M.
When is Lisata Therapeutics’s upcoming earnings report date?
Lisata Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 8 days.
How were Lisata Therapeutics’s earnings last quarter?
Lisata Therapeutics released its earnings results on Aug 17, 2026. The company reported -€0.288 earnings per share for the quarter.
Is Lisata Therapeutics overvalued?
According to Wall Street analysts Lisata Therapeutics’s price is currently Overvalued.
Does Lisata Therapeutics pay dividends?
Lisata Therapeutics does not currently pay dividends.
What is Lisata Therapeutics’s EPS estimate?
Lisata Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lisata Therapeutics have?
Lisata Therapeutics has 10,804,066 shares outstanding.
What happened to Lisata Therapeutics’s price movement after its last earnings report?
Lisata Therapeutics reported an EPS of -€0.288 in its last earnings report. Following the earnings report the stock price went up 1.754%.
Which hedge fund is a major shareholder of Lisata Therapeutics?
Currently, no hedge funds are holding shares in DE:8NE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lisata Therapeutics
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Technical Analysis
―
Aptevo Therapeutics
―
Citius Pharmaceuticals
―
Processa Pharmaceuticals
―
Apollomics
―